Literature DB >> 1464316

Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor.

Y Yamamura1, Y Kageyama, T Matuzaki, M Noda, Y Ikawa.   

Abstract

Erythropoietin receptor (EPOR) and interleukin-2 receptor beta chain (IL-2R beta) belong to the same cytokine receptor superfamily and have highly conserved sequences in their intracellular signaling domain. However, common downstream signaling pathways of these receptors have not been demonstrated. In the present study, we introduced and expressed the murine EPOR in murine IL-2-, IL-3- and IL-5-dependent cell lines and analyzed their growth response to EPO. We found that the expression of EPOR induced EPO dependence in IL-3-dependent BAF-B03 and IL-5-dependent Y16 cells but not in IL-2-dependent CTLL-2 cells, although the EPOR-expressing CTLL-2 cell lines could bind and internalize EPO as efficiently as the BAF-B03-derived cell lines. Additional expression of AIC2B, a common signal transducer for IL-3R, IL-5R and GM-CSFR, made no difference to the EPO responsiveness of the EPOR-expressing CTLL-2 cell lines. These results suggest that the cellular components required for the transduction of EPOR signal and IL-2R signal are at least partially different, and this difference cannot be explained solely by the absence of AIC2B.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464316      PMCID: PMC556968          DOI: 10.1002/j.1460-2075.1992.tb05597.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  59 in total

1.  Erythropoietin is both a mitogen and a survival factor.

Authors:  J L Spivak; T Pham; M Isaacs; W D Hankins
Journal:  Blood       Date:  1991-03-15       Impact factor: 22.113

2.  Hygromycin B phosphotransferase as a selectable marker for DNA transfer experiments with higher eucaryotic cells.

Authors:  K Blochlinger; H Diggelmann
Journal:  Mol Cell Biol       Date:  1984-12       Impact factor: 4.272

3.  Cloning of the gamma chain of the human IL-2 receptor.

Authors:  T Takeshita; H Asao; K Ohtani; N Ishii; S Kumaki; N Tanaka; H Munakata; M Nakamura; K Sugamura
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

4.  Identification of a cell surface 105 kd protein (Aic-2 antigen) which binds interleukin-3.

Authors:  S Yonehara; A Ishii; M Yonehara; S Koyasu; A Miyajima; J Schreurs; K Arai; I Yahara
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

5.  Cloning and expression of a gene encoding an interleukin 3 receptor-like protein: identification of another member of the cytokine receptor gene family.

Authors:  D M Gorman; N Itoh; T Kitamura; J Schreurs; S Yonehara; I Yahara; K Arai; A Miyajima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

6.  Interaction of the IL-2 receptor with the src-family kinase p56lck: identification of novel intermolecular association.

Authors:  M Hatakeyama; T Kono; N Kobayashi; A Kawahara; S D Levin; R M Perlmutter; T Taniguchi
Journal:  Science       Date:  1991-06-14       Impact factor: 47.728

7.  The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains.

Authors:  A D D'Andrea; A Yoshimura; H Youssoufian; L I Zon; J W Koo; H F Lodish
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

8.  Proliferative action of erythropoietin is associated with rapid protein tyrosine phosphorylation in responsive B6SUt.EP cells.

Authors:  F W Quelle; D M Wojchowski
Journal:  J Biol Chem       Date:  1991-01-05       Impact factor: 5.157

9.  Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation.

Authors:  M P Carroll; J L Spivak; M McMahon; N Weich; U R Rapp; W S May
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

10.  Functional domains of the granulocyte colony-stimulating factor receptor.

Authors:  R Fukunaga; E Ishizaka-Ikeda; C X Pan; Y Seto; S Nagata
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  9 in total

1.  Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response.

Authors:  F W Quelle; D Wang; T Nosaka; W E Thierfelder; D Stravopodis; Y Weinstein; J N Ihle
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  Absence of cytokine receptor-dependent specificity in red blood cell differentiation in vivo.

Authors:  M A Goldsmith; A Mikami; Y You; K D Liu; L Thomas; P Pharr; G D Longmore
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

3.  Erythropoietin and interleukin-2 activate distinct JAK kinase family members.

Authors:  D L Barber; A D D'Andrea
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

4.  Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development.

Authors:  Nick Carpino; William E Thierfelder; Ming-shi Chang; Chris Saris; Steven J Turner; Steven F Ziegler; James N Ihle
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

5.  Activated Ki-Ras complements erythropoietin signaling in CTLL-2 cells, inducing tyrosine phosphorylation of a 160-kDa protein.

Authors:  Y Yamamura; M Noda; Y Ikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

6.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

7.  Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways.

Authors:  H Wakao; N Harada; T Kitamura; A L Mui; A Miyajima
Journal:  EMBO J       Date:  1995-06-01       Impact factor: 11.598

8.  Epo receptors are not detectable in primary human tumor tissue samples.

Authors:  Steve Elliott; Susan Swift; Leigh Busse; Sheila Scully; Gwyneth Van; John Rossi; Carol Johnson
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

9.  Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO.

Authors:  Chantiya Chanswangphuwana; David S J Allan; Mala Chakraborty; Robert N Reger; Richard W Childs
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.